added names of new variants

README.md

@@ -58,7 +58,7 @@ Contains nanobody structures generated by AlphaFold-2. The ColabFold notebook fr
 
 ### ```integrative_modeling_VOC```
 The overall content is similar as above. Main differences are -
-- integrative modeling and analysis scripts now have additional command line flags for selecting SARS-CoV-2 variant (Wuhan, Delta, Omicron BA.1, BA.4)
+- integrative modeling and analysis scripts now have additional command line flags for selecting SARS-CoV-2 variant (Wuhan, Delta, Omicron BA.1, BA.4, XBB.1, BQ.1.1)
 - results contain scripts to heat-map relative binding (Kd) or potency (IC50) data on consensus epitopes of nanobodies belonging to the same group.
 
 <br>
@@ -80,4 +80,4 @@ _Parallelizable_: Yes
 _Publications_:
 - Fred D. Mast, Peter C. Fridy, Natalia E. Ketaren, Junjie Wang, Erica Y. Jacobs, Jean Paul Olivier, Tanmoy Sanyal, Kelly R. Molloy, Fabian Schmidt, Magdalena Rutkowska, Yiska Weisblum, Lucille M. Rich, Elizabeth R. Vanderwall, Nicholas Dambrauskas, Vladimir Vigdorovich, Sarah Keegan, Jacob B Jiler, Milana E. Stein, Paul Dominic B. Olinares, Louis Herlands, Theodora Hatziioannou, D. Noah Sather, Jason S. Debley, David Fenyo, Andrej Sali, Paul D. Bieniasz, John D. Aitchison, Brian T. Chait, Michael P. Rout, [*Highly synergistic combinations of nanobodies that target SARS-CoV-2 and are resistant to escape*, eLife 2021; 10e73027](https://elifesciences.org/articles/73027)
 
-- Natalia E. Ketaren, Fred D. Mast, Peter C. Fridy, Jean Paul Olivier, Tanmoy Sanyal, Andrej Sali, Brian T. Chait, Michael P. Rout, John D. Aitchison, [*Nanobody repertoire generated against the spike protein of ancestral SARS-CoV-2 remains efficacious against the rapidly evolving virus*, Biorxiv 2023](https://www.biorxiv.org/content/10.1101/2023.07.14.549041v1)
+- Natalia E. Ketaren, Fred D. Mast, Peter C. Fridy, Jean Paul Olivier, Tanmoy Sanyal, Andrej Sali, Brian T. Chait, Michael P. Rout, John D. Aitchison, [*Nanobody repertoire generated against the spike protein of ancestral SARS-CoV-2 remains efficacious against the rapidly evolving virus*, Biorxiv 2023](https://www.biorxiv.org/content/10.1101/2023.07.14.549041v1)